Literature DB >> 16287993

Type I insulin-like growth factor receptor as a therapeutic target in cancer.

Bradley S Miller1, Douglas Yee.   

Abstract

Data from experimental model systems and population studies have implicated type I insulin-like growth factor receptor (IGF1R) signaling in many different human cancers. Drugs to disrupt IGF1R function have been developed and are now entering clinical trial. This brief review will identify key areas to consider as these clinical trials move forward.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16287993     DOI： 10.1158/0008-5472.CAN-05-2752

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  35 in total

Review 1.  Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.

Authors:  Sripriya Raman; Adda Grimberg; Steven G Waguespack; Bradley S Miller; Charles A Sklar; Lillian R Meacham; Briana C Patterson
Journal:  J Clin Endocrinol Metab       Date:  2015-04-03       Impact factor: 5.958

2.  Associations between genetic polymorphisms of insulin-like growth factor axis genes and risk for age-related macular degeneration.

Authors:  Chung-Jung Chiu; Yvette P Conley; Michael B Gorin; Gary Gensler; Chao-Qiang Lai; Fu Shang; Allen Taylor
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-25       Impact factor: 4.799

3.  Decreased proliferative capacity of aged dermal fibroblasts in a three dimensional matrix is associated with reduced IGF1R expression and activation.

Authors:  Itay Bentov; Mamatha Damodarasamy; Stephen Plymate; May J Reed
Journal:  Biogerontology       Date:  2014-04-26       Impact factor: 4.277

Review 4.  Insulin-like growth factor pathway aberrations and gastric cancer; evaluation of prognostic significance and assessment of therapeutic potentials.

Authors:  Omar Abdel-Rahman
Journal:  Med Oncol       Date:  2014-12-09       Impact factor: 3.064

5.  Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer.

Authors:  Xiaodong Tian; Kun Hao; Changfu Qin; Kun Xie; Xuehai Xie; Yinmo Yang
Journal:  Dig Dis Sci       Date:  2013-04-16       Impact factor: 3.199

Review 6.  The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors.

Authors:  Martin G Belinsky; Lori Rink; Kathy Q Cai; Michael F Ochs; Burton Eisenberg; Min Huang; Margaret von Mehren; Andrew K Godwin
Journal:  Cell Cycle       Date:  2008-10-07       Impact factor: 4.534

7.  Targeting for insulin-like growth factor-I receptor with short hairpin RNA for human digestive/gastrointestinal cancers.

Authors:  Yu Wang; Yasushi Adachi; Arisa Imsumran; Hiroyuki Yamamoto; Wenhua Piao; Hua Li; Masanori Ii; Yoshiaki Arimura; Mi Young Park; Dalrae Kim; Choon-Taek Lee; David P Carbone; Kohzoh Imai; Yasuhisa Shinomura
Journal:  J Gastroenterol       Date:  2009-11-10       Impact factor: 7.527

8.  Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.

Authors:  Liang Cao; Yunkai Yu; Isaac Darko; Duane Currier; Linnia H Mayeenuddin; Xiaolin Wan; Chand Khanna; Lee J Helman
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

9.  Anti-insulin growth factor receptor therapy in Ewing sarcoma.

Authors:  Michael S Isakoff; Neyssa Marina
Journal:  F1000 Med Rep       Date:  2009-08-17

10.  Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma.

Authors:  B A Jacobson; A De; M G Kratzke; M R Patel; J Jay-Dixon; B A Whitson; A A Sadiq; P B Bitterman; V A Polunovsky; R A Kratzke
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.